In Phase II trial, treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression of non-alcoholic fatty liver disease to its more dangerous form: non-alcoholic steatohepatitis UNIVERSITY OF CALIFORNIA – SAN DIEGO Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San...